These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 39028785)
41. A case of vasovagal syncope with convulsions--the effects of midodrine hydrochloride. Koyama S; Matsubara T; Aizawa Y; Ohshima M; Yamaguchi T; Yamazaki Y; Igarashi Y; Tamura Y; Yamazoe M; Izumi T Jpn Circ J; 1992 Sep; 56(9):950-4. PubMed ID: 1383579 [TBL] [Abstract][Full Text] [Related]
42. Comparison of frequency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope. Alegria JR; Gersh BJ; Scott CG; Hodge DO; Hammill SC; Shen WK Am J Cardiol; 2003 Jul; 92(1):82-4. PubMed ID: 12842256 [No Abstract] [Full Text] [Related]
43. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. Piwinski SE; Jankovic J; McElligott MA J Clin Pharmacol; 1994 May; 34(5):466-71. PubMed ID: 7522240 [TBL] [Abstract][Full Text] [Related]
44. Current approach to the treatment of vasovagal syncope in adults. Hatoum T; Raj S; Sheldon RS Intern Emerg Med; 2023 Jan; 18(1):23-30. PubMed ID: 36117230 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. Lamarre-Cliche M; Souich Pd; Champlain Jd; Larochelle P Clin Ther; 2008 Sep; 30(9):1629-38. PubMed ID: 18840368 [TBL] [Abstract][Full Text] [Related]
46. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Sheldon R; Connolly S; Rose S; Klingenheben T; Krahn A; Morillo C; Talajic M; Ku T; Fouad-Tarazi F; Ritchie D; Koshman ML; Circulation; 2006 Mar; 113(9):1164-70. PubMed ID: 16505178 [TBL] [Abstract][Full Text] [Related]
48. Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Flevari P; Leftheriotis D; Repasos E; Katsaras D; Katsimardos A; Lekakis J Europace; 2017 Jan; 19(1):127-131. PubMed ID: 27702846 [TBL] [Abstract][Full Text] [Related]
49. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. Flevari P; Livanis EG; Theodorakis GN; Zarvalis E; Mesiskli T; Kremastinos DT J Am Coll Cardiol; 2002 Aug; 40(3):499-504. PubMed ID: 12142117 [TBL] [Abstract][Full Text] [Related]
50. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. Connolly SJ; Sheldon R; Roberts RS; Gent M J Am Coll Cardiol; 1999 Jan; 33(1):16-20. PubMed ID: 9935002 [TBL] [Abstract][Full Text] [Related]
51. Severe cardioinhibitory vasovagal syncope in sleep and supine posture. Xu Z; Bower S; Seneviratne U Epileptic Disord; 2014 Mar; 16(1):101-6. PubMed ID: 24556476 [TBL] [Abstract][Full Text] [Related]
52. Observations on midodrine in a case of vasodepressor neurogenic syncope. Ward C; Kenny RA Clin Auton Res; 1995 Oct; 5(5):257-60. PubMed ID: 8563457 [TBL] [Abstract][Full Text] [Related]
53. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study. Raviele A; Brignole M; Sutton R; Alboni P; Giani P; Menozzi C; Moya A Circulation; 1999 Mar; 99(11):1452-7. PubMed ID: 10086969 [TBL] [Abstract][Full Text] [Related]
54. Implementation of supervised physical training to reduce vasovagal syncope recurrence: A randomized controlled trial. Aghajani F; Tavolinejad H; Sadeghian S; Bozorgi A; Jalali A; Vasheghani-Farahani A; Yadangi S; Niazi S; Poopak A; Tajdini M J Cardiovasc Electrophysiol; 2022 Aug; 33(8):1863-1870. PubMed ID: 35634869 [TBL] [Abstract][Full Text] [Related]
55. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. Connolly SJ; Sheldon R; Thorpe KE; Roberts RS; Ellenbogen KA; Wilkoff BL; Morillo C; Gent M; JAMA; 2003 May; 289(17):2224-9. PubMed ID: 12734133 [TBL] [Abstract][Full Text] [Related]
57. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. Di Girolamo E; Di Iorio C; Sabatini P; Leonzio L; Barbone C; Barsotti A J Am Coll Cardiol; 1999 Apr; 33(5):1227-30. PubMed ID: 10193720 [TBL] [Abstract][Full Text] [Related]
58. Quality of life improves in vasovagal syncope patients after clinical trial enrollment regardless of fainting in follow-up. Ng J; Sheldon RS; Maxey C; Ritchie D; Raj V; Exner DV; Raj SR Auton Neurosci; 2019 Jul; 219():42-48. PubMed ID: 31122600 [TBL] [Abstract][Full Text] [Related]
59. Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Theodorakis GN; Leftheriotis D; Livanis EG; Flevari P; Karabela G; Aggelopoulou N; Kremastinos DT Europace; 2006 Mar; 8(3):193-8. PubMed ID: 16627439 [TBL] [Abstract][Full Text] [Related]
60. The economics of treating vasovagal syncope. Sutton R; Petersen ME Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 2):849-50. PubMed ID: 9080526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]